A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer-Reference-Cited by-同舟云学术

A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer

Published:2012-11 Issue:2 Volume:98 Page:271-284
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Alves Carlos,Batel-Marques Francisco,Macedo Ana F.

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference39 articles.

1. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes;Nathan;Diabetes Care,2009

2. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study;Drucker;Lancet,2008

3. Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211)

4. Byetta drug approval package. FDA/Centre for Drug Evaluation and Research, available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021773_ByettaTOC.cfm; 2005 [access2nd edn3.05.12].

5. European public assessment report (EPAR) for Byetta. EMA/Committee for Medicinal Products for Human Use, available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000698/human_med_000682.jsp&mid=WC0b01ac058001d124; 2006 [access2nd edn3.05.12].

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials;Diabetes, Obesity and Metabolism;2023-11-29

2. Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS);Frontiers in Pharmacology;2023-11-17

3. The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease;Expert Review of Clinical Pharmacology;2023-10-27

4. The Role of Real-World Evidence in Treatment Decision-Making, Regulatory Assessment, and Understanding the Perspectives of People with Type 2 Diabetes: Examples with Gliclazide MR;Diabetes Therapy;2023-08-21

5. Acute Pancreatitis in a Patient Taking Semaglutide;Cureus;2023-08-19